Posted by Michael Wonder on 01 Aug 2024
Guardant Health’s FDA approved Shield blood test now commercially available in US as a primary screening option for colorectal cancer
1 August 2024 - FDA approval announced earlier this week makes Shield first blood test that is approved for primary screening of colorectal cancer and meets coverage requirements for Medicare reimbursement.
Guardant Health today announced that its Shield blood test, recently approved by the US FDA, is now covered by Medicare and is commercially available in the US as the first FDA approved blood test for primary colorectal cancer screening.
